You are here



Perinatal Stem Cell Society partners with PRESENT Regenerative Medicine
Feb 2017   Congress taking place 19-21 May 2017 in Teaneck NJ carries 16 CME credits on evidence-based research and products derived from Perinatal sources.
J.E. Davies - University of Toronto
Feb 2017   Despite the hurdles, great therapeutic value can be gained from the MSCs in the Wharton’s Jelly of Cord Tissue, which are being employed in an ever-increasing portfolio of indications.
CellOptima technoloogy to store stem cells from cord tissue lining
Feb 2017   Available exclusively from Cordlife, CellOptima™ is a proprietary technology which can isolate and expand two types of stem cells: MSC and EpSC, from the lining of the newborn's umbilical cord.


Number of advanced cell therapy clinical trials per year with perinatal cells
Jan 2017   There are more advanced cell therapy clinical trials with other sources of perinatal cells than there are with cord blood, either cumulatively or by year.
Newborn With Brain Injury Treated With Own Stem Cells Improving
Jan 2017   When he was 12 days old Jack became the youngest person ever to undergo stem cell therapy in Canada and the first person in the country to be treated for HIE with stem cells.


Dr. Elisabeth Semple
Dec 2016   Literature review finds umbilical cord clamping at 30-60 secs after term birth ensures safe outcome for baby and adequate cord blood collection.
Rodica Ciubotariu, MD PhD
Dec 2016   Fraction of cord blood collections suitable for transplant goes down by a factor of 7 when cord clamping delay exceeds 1 minute.


Correlation between public and family cord blood banks per country in 2015
Nov 2016   Slides from Parent's Guide to Cord Blood Foundation at Phacilitate Cord Blood and Tissue Webinar 16 Nov. 2016. All presentations will be archived.
Babycell cord blood transplant patient Neha with her donor brother
Nov 2016   Neha is now a healthy six year old after a cord blood transplant from her brother thanks to the family cord blood bank Babycell in India.
Nov 2016   We see rapid growth in AMP-based injectable products being offered in the U.S., and targeted specifically for allogeneic use. Does this meet FDA guidance?